Post-Operative Use of Dopamine Agonist in Management of Remaining Nonfunctioning Pituitary Adenoma | ||||
| The Medical Journal of Cairo University | ||||
| Article 88, Volume 89, June, June 2021, Page 1155-1162 PDF (466.67 K) | ||||
| DOI: 10.21608/mjcu.2021.185003 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| AHMED ADEL AYAD, M.D. | ||||
| The Department of Neurosurgery, Faculty of Medicine, Al Azhar University | ||||
| Abstract | ||||
| Abstract Background: Complete tumor elimination via transsphe-noidal surgical operation is frequently hard for large non-functioning pituitary adenomas (NFPAs). A confirmed medical treating might be beneficial for their managing. Aim of Study: To investigate the effectiveness of dopamine agonist medication in decreasing or avoiding the re-growing of NFPA after ward surgical operation. Patients and Methods: This was a prospective, randomized, clinical trial done in Al-Azhar University Hospitals was conducted on 20 patients experienced primary transsphenoidal surgical operation for pituitary adenoma management, the study was carried out through a period of 12 months from March 2020 to March 2021. Results: Tumour reduction rate of remaining cancer mass was significantly higher in medically-treated group, while tumour growing rate of remaining tumour mass was signifi-cantly elevated in controls. Conclusion: Cabergoline (dopamine agonist was an ef-fective medication for the treatment of remaining NFPA, and its usage was accompanying with an elevated tumour shrink-agerates. | ||||
| Keywords | ||||
| Dopamine Agonists (DA); Non-Functioning Pituitary Adenoma (NFPA) | ||||
|
Statistics Article View: 111 PDF Download: 115 |
||||
